skyrizi 75 mg/0.83 ml 2 prefilled syringe
سكايريزي 75 مجم /0.83 مل 2 حقنة معبأة
risankizumab · 75 mg/0.83 ml
65714EGP
- Active ingredient
- risankizumab
- Strength
- 75 mg/0.83 ml
- Form
- syringe
- Manufacturer
- abbvie ltd. > abbvie scientific office
- Route
- injection
Uses
Indicated for moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults.
Do not use if
History of serious hypersensitivity reaction to risankizumab or any excipient.
Side effects
Common adverse effects include upper respiratory infections, headache, fatigue, injection-site reactions, and hypersensitivity reactions.
Warnings
Monitor for infections, tuberculosis, and hypersensitivity reactions.
How it works
Humanized monoclonal antibody that selectively inhibits interleukin-23 by binding its p19 subunit.
Storage
Store refrigerated at 2°C to 8°C. Do not freeze.